Optimizing HEK293-based viral vector production, part 1: cell lines and media

Cell & Gene Therapy Insights 2024; 10(1), 47

DOI: 10.18609/cgti.2024.009

Published: 7 February
Sandra Klausing, David Ede

Watch the video or view the poster to learn how to:

  • Quickly screen and optimize your media, transfection reagents, and cell lines 
  • Optimize your Critical Process Parameters (CPPs) with scaled-down models 
  • Learn Quality by Design (QbD) Approach for Viral Vector Production  
  • Use Innovation and Cutting Edge Technology to Unblock Bottlenecks and Accelerate AAV and LV Therapy Development and Manufacturing
  • This poster is part 1 of a two-part series; part 2 can be found here

Sandra has more than 17 years of experience in biotechnology, with an extensive background in cell culture technologies. She joined Xell in 2013 and later led its transition to becoming part of Sartorius. In her previous role as Manager of Media and Process Development, she focused on cell culture media and processes for gene therapy applications, specifically AAV and lentiviral vector production. She is currently Head of Product Development, Cell Line, and Media, focusing on PG cell line, media, and testing solutions.

David is a Biomedical and Chemical Engineer. He has degrees from the University of Utah and Oklahoma State University, and has a background in process development and manufacturing for viral vectors. In his current role as Process Technology Manager at Sartorius, David supports gene-based biotechnology stakeholders and helps bring their bioprocess from R&D to commercial scale.